Why is Bioxcel Therapeutics Inc (BTAI) Stock down?
BioXcel Therapeutics Stock (BTAI) dropped by 23.41% from $5.51 to $4.22 in the trading on Tuesday November 14, 2023. The reason why BTAI stock down today isnclude
- Weak third-quarter results: The biopharmaceutical company posted a loss of $50.5 million, or $1.72 a share, compared with $41.8 million, or $1.49 a share, in the same quarter a year ago. Analysts had been expecting a loss of $1.27 a share. Revenue of $341,000 missed analyst projections for $600,000
- Regulators' recommendation: BioXcel said that it is aligned with the U.S. Food and Drug Administration's recommendation for the Phase 3 trial of Igalmi as a treatment of agitation in bipolar disorders or schizophrenia to be conducted in the at-home setting.
BioXcel Therapeutics (BTAI) stock is plummeting 41.5% from $7.40 to $4.33 Monday. BioXcel published its second-quarter results before the market opened this morning and paired the release with news of a major restructuring initiative.
BioXcel's stock price fell 7.94% from $10.33 to $9.51 on the news that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired the company's securities.
BioXcel shares plummeted 63.8% from $17.67 to $6.39 after revealing a fraud investigation at its biggest study site.
Shares of BioXcel Therapeutics (BTAI) were down 25.5% from $25.93 to $19.32 on Thursday after the biotech company released the first part of a phase 3 trial for the therapy BXCL501 (dexmedetomidine) to treat acute agitation in bipolar disorders or schizophrenia.
Shares of BioXcel Therapeutics (BTAI) declined 5.35% from $21.48 to $20.33 after announcing that it has confidentially submitted a draft registration statement relating to the proposed initial public offering of its common stock following its conversion into a corporation.
BioXcel shares plummeted 15.9% from $24.56 to $20.66 regarding the Q4 2022 Earnings Call.
https://finance.yahoo.com/news/q4-2022-bioxcel-therapeutics-inc-073220029.html
BioXcel Therapeutics (BTAI) dipped 13.4% from $28.36 to $24.56 after issuing its financial results for the fourth quarter and full year ended Dec. 31, 2022 and provided an update on key strategic initiatives.
https://finance.yahoo.com/news/bioxcel-therapeutics-reports-fourth-quarter-120000852.html